ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TLCR Talecris Biotherapeutics Holdings Corp. (MM)

28.80
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Talecris Biotherapeutics Holdings Corp. (MM) NASDAQ:TLCR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 28.80 0 01:00:00

Talecris Biotherapeutics Holdings Corp. - Momentum

18/04/2011 1:00am

Zacks


Talecris Biotherapeutics Holdings Corp. (TLCR) recently hit a new all-time high after spending the last six months advancing along a very steady trend line. With an average earnings surprise of 9% over the last four quarters and estimates on the upswing, this Zacks #1 rank stock provides the right remedy for momentum.

Company Description

Telacris Bio therapeutics Holding Corp. is a biopharmaceutical company that specializes in the development of plasma-derived protein therapies worldwide with a market cap of $3.56 billion.

Our last major update on TLCR's business came in late February when the company reported strong Q4 results that included sharp gains from last year.

Fourth-Quarter Results

Revenue for the period was up 5% from last year to $411 million. Net looked even better, spiking to $17 million from $1.4 million last year.

The strong results were driven by solid gains in Gamunex-C/Gamunex IGIV revenue, which was up 10% from last year to $21 million.

Margin expansion also helped the cause, with gross margin climbing to 41.2% from 39.2% last year.

Financial Profile

The company has also been very focused on strengthening its balance sheet, with cash and equivalents jumping $133 million to $198 million against long-term debt and capital lease obligations of $605 million.

Estimates

We saw some movement in estimates off the good quarter, with the current year up 7 cents in the last two months to $1.81 while the next-year estimate gained 8 cents in the same time to $1.93, a solid 7% growth projection.

Valuation

But in spite of the solid gains, the valuation picture still looks solid, with a forward P/E of 15.5X, a decent discount to its peer average of 17X.

6-Month Chart

On the chart, shares recently surged into a new all-time high after trending higher for most of the last six months. Look for support from the trend line on any weakness, take a look below.

Michael Vodicka is the Momentum Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Momentum Trader Service.
 
TALECRIS BIOTHR (TLCR): Free Stock Analysis Report
 
Zacks Investment Research

1 Year Talecris Biotherapeutics Holdings Corp. (MM) Chart

1 Year Talecris Biotherapeutics Holdings Corp. (MM) Chart

1 Month Talecris Biotherapeutics Holdings Corp. (MM) Chart

1 Month Talecris Biotherapeutics Holdings Corp. (MM) Chart

Your Recent History

Delayed Upgrade Clock